Evidence map›Paper›PMID 37160884›Full record

ReviewTranslational psychiatry2023

Biological factors influencing depression in later life: role of aging processes and treatment implications.

Sarah M Szymkowicz, Andrew R Gerlach, Damek Homiack, Warren D Taylor

Open access · goldAbstract readReview
In one paragraph

Review in Translational psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 4 pooled it
22.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 4 syntheses or guidelines pooled it, 143 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Hippocampal Total, Subregion, and Subfield Volume Alterations in Late-Life Depression.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2026
    Article
  18. Article
  19. Article
  20. Antidepressant Augmentation of Antipsychotic Treatment in Schizophrenia: A Narrative Review.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Review

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Sarah M Szymkowicz *Center for Cognitive Medicine, Department of Psychiatry and Behavioral Science, Vanderbilt University Medical Center, Nashville, TN, USA.
Andrew R Gerlach *Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.
Damek HomiackDepartment of Psychiatry, University of Illinois-Chicago, Chicago, IL, USA.
Warren D TaylorCenter for Cognitive Medicine, Department of Psychiatry and Behavioral Science, Vanderbilt University Medical Center, Nashville, TN, USA. warren.d.taylor@vumc.org.ORCID 0000-0002-9975-3082
University of Illinois Chicago · USUniversity of Pittsburgh · USVanderbilt University Medical Center · USVA Tennessee Valley Healthcare System · US

Funding

Expansion of the Dopaminergic Dysfunction in Late-Life Depression Study (The D3 Study)R01MH123662 · NIMH · VANDERBILT UNIVERSITY MEDICAL CENTER · PI TAYLOR, WARREN D · 2020 to 2024
$7.4M
CLINICAL RESEARCH TRAINING IN LATE-LIFE MOOD DISORDERST32MH019986 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HOWARD J AIZENSTEIN, Carmen Andreescu · 1997 to 2026
$6.9M
1/3-Recurrence Markers, Cognitive Burden and Neurobiological Homeostasis in Late-life Depression (Rembrandt)R01MH121620 · NIMH · VANDERBILT UNIVERSITY MEDICAL CENTER · PI TAYLOR, WARREN D · 2020 to 2024
$5.3M
Recurrence markers, cognitive burden and neurobiological homeostasis in latelife depression (REMBRANDT) - SupplementR01MH121619 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ANDREESCU, CARMEN · 2020 to 2024
$5.1M
3/3-Recurrence markers, cognitive burden and neurobiological homeostasis in late-life depressionR01MH121384 · NIMH · UNIVERSITY OF ILLINOIS AT CHICAGO · PI AJILORE, OLUSOLA A. · 2020 to 2024
$3.0M
Nicotinic Modulation of the Cognitive Control System in Late-Life DepressionR33MH122464 · NIMH · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ANDREWS, PATRICIA SERRANO · 2023 to 2025
$2.8M
Nicotinic Modulation of the Cognitive Control System in Late-Life DepressionR61MH122464 · NIMH · VANDERBILT UNIVERSITY MEDICAL CENTER · PI TAYLOR, WARREN D · 2020 to 2021
$1.9M
NIMH NIH HHS L30 MH127619NIMH NIH HHS R01 MH121384NIMH NIH HHS R01 MH121619NIMH NIH HHS R01 MH121620NIMH NIH HHS R01 MH123662NIMH NIH HHS R33 MH122464NIMH NIH HHS R61 MH122464NIMH NIH HHS T32 MH019986
6 · The paper itself

Abstract

Late-life depression occurring in older adults is common, recurrent, and malignant. It is characterized by affective symptoms, but also cognitive decline, medical comorbidity, and physical disability. This behavioral and cognitive presentation results from altered function of discrete functional brain networks and circuits. A wide range of factors across the lifespan contributes to fragility and vulnerability of those networks to dysfunction. In many cases, these factors occur earlier in life and contribute to adolescent or earlier adulthood depressive episodes, where the onset was related to adverse childhood events, maladaptive personality traits, reproductive events, or other factors. Other individuals exhibit a later-life onset characterized by medical comorbidity, pro-inflammatory processes, cerebrovascular disease, or developing neurodegenerative processes. These later-life processes may not only lead to vulnerability to the affective symptoms, but also contribute to the comorbid cognitive and physical symptoms. Importantly, repeated depressive episodes themselves may accelerate the aging process by shifting allostatic processes to dysfunctional states and increasing allostatic load through the hypothalamic-pituitary-adrenal axis and inflammatory processes. Over time, this may accelerate the path of biological aging, leading to greater brain atrophy, cognitive decline, and the development of physical decline and frailty. It is unclear whether successful treatment of depression and avoidance of recurrent episodes would shift biological aging processes back towards a more normative trajectory. However, current antidepressant treatments exhibit good efficacy for older adults, including pharmacotherapy, neuromodulation, and psychotherapy, with recent work in these areas providing new guidance on optimal treatment approaches. Moreover, there is a host of nonpharmacological treatment approaches being examined that take advantage of resiliency factors and decrease vulnerability to depression. Thus, while late-life depression is a recurrent yet highly heterogeneous disorder, better phenotypic characterization provides opportunities to better utilize a range of nonspecific and targeted interventions that can promote recovery, resilience, and maintenance of remission.

Indexed as

Biological FactorsDepressionAdolescentAdultAgedAgingChildHumansHypothalamo-Hypophyseal SystemPituitary-Adrenal SystemBiological Factors

Identifiers

PMID37160884
PMCPMC10169845
OpenAlexW4376132007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.